Institute of Biophysics and Cell Engineering

http://ibp.org.by/  

Biomedical cell product "Human corneal limbus epithelial stem cells"

COUNTRY OF ORIGIN

Belarus

IDENTIFIER

BO4368

PUBLISHED

2021-10-22

LAST UPDATE

2021-10-22

DEADLINE

Linked profile in other language
Responsible
Alena Кniazeva
+375 17 251 5357
kniazeva@ibp.org.by
Summary
The Institute has developed a biomedical cell product (BCP) "Human corneal limbus epithelial stem cells" and a method of cell therapy in the treatment of keratitis and corneal dystrophies with its use. The Institute offers services for the treatment of diseases using the developed BCP under an outsourcing agreement.
Description
This biomedical cell product (BCP) is produced on the basis of autologous limbal epithelial stem cells (LESC) isolated from the patient's keratolimbal flap and cultured until a therapeutic dose is received.

Transplantation of BCP based on LESC is indicated for mechanical injuries, radiation and chemical burns of the cornea, recurrent corneal erosions, chronic keratitis, and keratitopathies of various origins (Stevens-Johnson syndrome, cicatricial pemphigoid, trachoma, congenital aniridia, etc.).

Local administration of cultured LESCs as part of complex cell therapy compensates for limbal insufficiency and ensures stable regeneration of the corneal epithelium, maintaining its regenerative properties for a long time, including for subsequent successful corneal transplantation.

The Institute offers services for the treatment of diseases using the developed biomedical cell product "Human corneal limbus epithelial stem cells" under an outsourcing agreement.
Advantages and Innovations
The use of BCP in clinical practice increases the effectiveness of existing treatment methods, does not cause complications and side effects.
Stage of development
Already on the market
Funding source
State budged
IPR status
Secret know-how
Sector group
Healthcare

Client information

Type
R&D institution
Year established
1973
NACE keywords
M.72.11 - Research and experimental development on biotechnology
Q.86.90 - Other human health activities
Already engaged in transnational cooperation
Yes
Additional comments
Over the past 10 years, the Institute has carried out a number of international contracts and agreements within the framework of the Framework Programs of the European Union, as well as with leading research centers, foundations, societies:
FP7-HEALTH-2007-4.1-8 «Promotion and facilitation of international cooperation with Eastern European and Central Asian Countries» (EECAlink, Nr. 223359), 2009-2011;

UNESCO № IAP 3240246593/011/027-Minsk « Science Academies in the Central and Eastern Europe and their Role in Knowledge-based Society», 2010-2011;

FP7-PEAPLE-2012-IRSES «Development of Nanotechnology based Biosensors for Agriculture» (PIRSES-GA-2012-318520), 2012-2016;

FP7-PEAPLE-2012-IRSES «EU-Belarus-Russia Network in Nanomaterials-Driven Anti-Cancer Gene Therapy» (PIRSES-GA-2012-316730), 2013-2017;

FP7-PEOPLE-2011-IIF-299194 «Optical real-time imaging of inhibitory GABAA receptors activity using chimeric GABA channel subunit» («ImagingGABA» Nr 299194) 2013-2015;

«INNOVIMMUNE: Baltic Platform for Innovative Immunotherapies», Nr 19806/2016,2016-2018;

NAWA IAP «Strengthening and spreading international partnership activities of the Faculty of Biology and Environmental Protection for interdisciplinary research and innovation of the University of Lodz» (№ PPI/APM/2018/1/00007/U/001) 2019-2020;

H2020-MSCA-RISE-2017 «Novel 1D photonic metal oxide nanostructures for early stage cancer detection» («CanBioSe», Nr 778157) 2018-2021:

The International Organization for Neurochemistry (ISN); Takeda Science Foundation; The Karpilo-Landau Society; Swiss National Science Foundation; University of Eastern Finland; World Federation of Scientists to Support Research, etc.
Languages spoken
English
Russian

Information about partnership

Type of partnership considered
Outsourcing agreement
Type and role of partner sought
Consumers interested in receiving services for the treatment of diseases using the developed biomedical cell product "Human corneal limbus epithelial stem cells" within the framework of an outsourcing agreement.
Type and size of partner sought
251-500
SME <= 10
SME 11-50
SME 51-250

Attachments

Количество уникальных просмотров в одной сессии: 79
Статистика ведется с 23.10.2021 00:54:17